HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: dc06-2192v1 30/5/1092    most recent Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kleefstra, N. Articles by Bilo, H. J.G. Search for Related Content PubMed PubMed Citation Articles by Kleefstra, N. Articles by Bilo, H. J.G. Social Bookmarking                What's this?

Chromium Treatment Has No Effect in Patients With Type 2 Diabetes in a Western Population

A randomized, double-blind, placebo-controlled trial

¹ Diabetes Centre, Isala Clinics, Zwolle, the Netherlands
² Langerhans Medical Research Group, Zwolle, the Netherlands
³ Department of Internal Medicine, University Medical Center Groningen, Groningen, the Netherlands
⁴ Department of General Practice, University of Groningen, Groningen, the Netherlands

Address correspondence and reprint requests to Nanne Kleefstra, MD, Diabetes Centre, Isala Clinics, P.O. Box 10400, 8000 GK Zwolle, Netherlands. E-mail: kleefstra{at}langerhans.com

OBJECTIVE—Chromium treatment has been reported to improve glycemic control in patients with type 2 diabetes. However, concern exists about the possible toxic effects of chromium picolinate. The aim of this study was to determine the effect of chromium treatment in the form of chromium yeast on glycemic control in a Western population of patients with type 2 diabetes who were being treated with oral hypoglycemic agents.

RESEARCH DESIGN AND METHODS—In this 6-month, double-blind study, patients with moderate glycemic control, being treated with oral hypoglycemic agents, were randomly assigned to receive either a placebo or treatment with 400 µg of chromium daily in the form of chromium yeast. The primary efficacy parameter was a change in A1C. Secondary end points were changes in lipid profile, BMI, blood pressure, body fat, and insulin resistance.

RESULTS—No differences were found for the change in A1C between the intervention and placebo groups, nor were any differences found between the groups for the secondary end points.

CONCLUSIONS—There is no evidence that chromium in the form of chromium yeast is effective in improving glycemic control in Western patients with type 2 diabetes who are taking oral hypoglycemic agents.

Abbreviations: ALT, alanine aminotransferase • CONSORT, Consolidated Standards of Reporting Trials • GLM, general linear model • HOMA-IR, homeostasis model assessment of insulin resistance

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				N. Kleefstra, S. T. Houweling, and H. J.G. Bilo Effect of Chromium Supplementation on Glucose Metabolism and Lipids: A Systematic Review of Randomized Controlled Trials: Response to Balk et al. Diabetes Care, September 1, 2007; 30(9): e102 - e102. [Full Text] [PDF]